Cargando…

Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments

BACKGROUND: Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera of patients with malignant diseases. METHODS: We investigated the course of nucleosomal DNA, thymidine kinase, lactate dehydrogenase and leukocytes in sera of 25 patients with acute myeloid leukemia during th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Susanne, Holdenrieder, Stefan, Stieber, Petra, Haferlach, Torsten, Schalhorn, Andreas, Braess, Jan, Nagel, Dorothea, Seidel, Dietrich
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1555596/
https://www.ncbi.nlm.nih.gov/pubmed/16734907
http://dx.doi.org/10.1186/1471-2407-6-143
_version_ 1782129361912070144
author Mueller, Susanne
Holdenrieder, Stefan
Stieber, Petra
Haferlach, Torsten
Schalhorn, Andreas
Braess, Jan
Nagel, Dorothea
Seidel, Dietrich
author_facet Mueller, Susanne
Holdenrieder, Stefan
Stieber, Petra
Haferlach, Torsten
Schalhorn, Andreas
Braess, Jan
Nagel, Dorothea
Seidel, Dietrich
author_sort Mueller, Susanne
collection PubMed
description BACKGROUND: Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera of patients with malignant diseases. METHODS: We investigated the course of nucleosomal DNA, thymidine kinase, lactate dehydrogenase and leukocytes in sera of 25 patients with acute myeloid leukemia during the first cycle of induction chemotherapy and tested their power to distinguish between patients with complete remission and those with no remission. RESULTS: Almost all patients showed strongly decreasing levels of nucleosomal DNA during the first week, in some cases after initial peaks. In overall analysis of variance, DNA levels could clearly distinguish between patients with complete remission, who had higher DNA values, and those with insufficient response (p = 0.017). The area under the curve of DNA values of days 2–4 after start of therapy (AUC 2–4) discriminated between both groups with a sensitivity of 56% at a specificity of 100%. Further, pretherapeutic levels and AUC 2–4 of nucleosomal DNA correlated significantly with blast reduction after 16 days. A tendency to higher levels in patients with complete response was also found for thymidine kinase, lactate dehydrogenase and leukocytes, however the difference did not reach the level of significance (p = 0.542, p = 0.260, and p = 0.144, respectively). CONCLUSION: Our results indicate that nucleosomal DNA fragments are valuable markers for the early prediction of therapeutic efficacy in patients with acute myeloid leukemia.
format Text
id pubmed-1555596
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15555962006-08-26 Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments Mueller, Susanne Holdenrieder, Stefan Stieber, Petra Haferlach, Torsten Schalhorn, Andreas Braess, Jan Nagel, Dorothea Seidel, Dietrich BMC Cancer Research Article BACKGROUND: Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera of patients with malignant diseases. METHODS: We investigated the course of nucleosomal DNA, thymidine kinase, lactate dehydrogenase and leukocytes in sera of 25 patients with acute myeloid leukemia during the first cycle of induction chemotherapy and tested their power to distinguish between patients with complete remission and those with no remission. RESULTS: Almost all patients showed strongly decreasing levels of nucleosomal DNA during the first week, in some cases after initial peaks. In overall analysis of variance, DNA levels could clearly distinguish between patients with complete remission, who had higher DNA values, and those with insufficient response (p = 0.017). The area under the curve of DNA values of days 2–4 after start of therapy (AUC 2–4) discriminated between both groups with a sensitivity of 56% at a specificity of 100%. Further, pretherapeutic levels and AUC 2–4 of nucleosomal DNA correlated significantly with blast reduction after 16 days. A tendency to higher levels in patients with complete response was also found for thymidine kinase, lactate dehydrogenase and leukocytes, however the difference did not reach the level of significance (p = 0.542, p = 0.260, and p = 0.144, respectively). CONCLUSION: Our results indicate that nucleosomal DNA fragments are valuable markers for the early prediction of therapeutic efficacy in patients with acute myeloid leukemia. BioMed Central 2006-05-30 /pmc/articles/PMC1555596/ /pubmed/16734907 http://dx.doi.org/10.1186/1471-2407-6-143 Text en Copyright © 2006 Mueller et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mueller, Susanne
Holdenrieder, Stefan
Stieber, Petra
Haferlach, Torsten
Schalhorn, Andreas
Braess, Jan
Nagel, Dorothea
Seidel, Dietrich
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title_full Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title_fullStr Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title_full_unstemmed Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title_short Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
title_sort early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal dna fragments
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1555596/
https://www.ncbi.nlm.nih.gov/pubmed/16734907
http://dx.doi.org/10.1186/1471-2407-6-143
work_keys_str_mv AT muellersusanne earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT holdenriederstefan earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT stieberpetra earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT haferlachtorsten earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT schalhornandreas earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT braessjan earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT nageldorothea earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments
AT seideldietrich earlypredictionoftherapyresponseinpatientswithacutemyeloidleukemiabynucleosomaldnafragments